Assessing an Oral Bruton Tyrosine Kinase Inhibitor, DZD9008 in Patients Who Have Non-Hodgkin B-cell Lymphoma (WU-KONG3)

NCT04148742 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Clinical development strategy adjustment, non-safety reason

Conditions

Non-Hodgkin's B-cell Lymphoma

Interventions

DRUG: DZD9008

Sponsor

Dizal Pharmaceuticals